The prevalence of TP53 and other mutations such as KMT2D and NOTCH1 provides valuable insights into tumorigenesis, while distinctions between primary and metastatic tumors reveal potential markers for metastasis that could be used to guide treatment decisions. The gene discussed is TP53; the disease is metastatic neoplasm.